Contribute Try STAT+ Today

Seeking to quickly widen global access to Covid-19 vaccines, a group of academics and patient advocates is urging the Biden administration to use a key patent owned by the U.S. government to boost manufacturing and distribution of the Moderna (MRNA) shot.

In a letter to federal officials, the group noted that a soon-to-be-issued-patent covering the use of spike proteins in the vaccine was jointly developed by the company and the National Institute of Allergy and Infectious Diseases. The patent has not been licensed to Moderna; the group maintains it is an “important policy tool” that can be used to ensure any licensing agreement fosters greater access.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.